Biogen
BIIB
1,031 hedge funds and large institutions have $34.2B invested in Biogen in 2022 Q4 according to their latest regulatory filings, with 159 funds opening new positions, 327 increasing their positions, 359 reducing their positions, and 95 closing their positions.
67% more first-time investments, than exits
New positions opened: 159 | Existing positions closed: 95
18% more capital inflows, than outflows
Capital inflows: $2.68B | Capital outflows: $2.28B
14% more funds holding in top 10
Funds holding in top 10: 22 → 25 (+3)
5% more funds holding
Funds holding: 986 → 1,031 (+45)
0.53% more ownership
Funds ownership: 85.26% → 85.79% (+0.53%)
9% less repeat investments, than reductions
Existing positions increased: 327 | Existing positions reduced: 359
14% less call options, than puts
Call options by funds: $1.29B | Put options by funds: $1.51B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$309M |
| 2 |
BlackRock
New York
|
+$117M |
| 3 |
Deep Track Capital
Greenwich,
Connecticut
|
+$84.7M |
| 4 |
Farallon Capital Management
San Francisco,
California
|
+$81.1M |
| 5 |
Barclays
London,
United Kingdom
|
+$81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$162M |
| 2 |
Avidity Partners Management
Dallas,
Texas
|
-$160M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$128M |
| 4 |
Goldman Sachs
New York
|
-$118M |
| 5 |
RA Capital Management
Boston,
Massachusetts
|
-$114M |
BIIB Hedge Fund Activity: Q4 2022 in Review
1,031 of the 6,244 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2022, worth a combined $34.2B — up 3.6% from $33B a quarter earlier.
Buyers outnumbered sellers: 159 funds opened new BIIB positions and 95 closed out — a net gain of 64 holders — while 327 added to existing stakes and 359 trimmed.
The largest buyer was Marshall Wace, adding an estimated $309M. The largest seller was Millennium Management, cutting an estimated $162M.
- 1,031 institutional investors held Biogen (BIIB) as of Q4 2022, up from 986 in Q3 2022.
- Funds reported $34.2B of Biogen stock for Q4 2022, up 3.6% quarter-over-quarter.
- 159 funds opened new Biogen positions in Q4 2022 and 95 closed out, a net change of +64 holders.
- The largest Biogen buyer in Q4 2022 was Marshall Wace, an estimated $309M added.
- The largest Biogen seller in Q4 2022 was Millennium Management, an estimated $162M sold.
Based on aggregated 13F filings for Q4 2022.